银屑病关节炎治疗进展

Advances in the management of psoriatic arthritis

银屑病关节炎(psoriatic arthritis,PsA)是一种累及肌肉骨骼、皮肤、指甲等组织的慢性炎症性疾病。近十年来,随着早期诊断和治疗策略的提高,PsA治疗方法已经发生很大变化。靶向细胞因子、受体和信号分子的新型生物制剂获得较快发展。TNF-α阻断剂包括阿达木单抗(adalimumab)、依那西普(etanercept)、戈利木单抗(golimumab)和英夫利昔单抗(infliximab)是治疗PsA革新的代表。新的抗TNF-α制剂赛妥珠单抗(certolizumab)以及针对IL-12和IL-23的全人源化优特克单抗(ustekinumab)也已经被推荐治疗PsA。靶向JAK/STAT(janus kinase/signal transducers and activators of transcription)信号通路的多个小分子药物近年来也被研发应用于临床治疗PsA。研发更好的靶向药物是今后治疗PsA的重要研究方向。

Psoriatic arthritis(PsA),which affects musculoskeletal structures,skin and nails,is a chronic inflammatory disease.The treatment of PsA has changed tremendously over the past decade owing to the improvement in early diagnosis and treatment strategies.TNF-αblockers,including adalimumab,etanercept,golimumab and infliximab,are representatives of a revolution in the treatment of PsA.Certolizumab(a new anti-TNF agent)and ustekinumab(a fully human monoclonal antibody against IL-12 and IL-23)are approved for the treatment of active PsA.In recent years,multiple small molecule drugs targeting Janus kinase/signal transducers and activators of transcription signaling pathway have been developed and applied to treat PsA in clinic.Developing better targeted drugs is an important research direction for the treatment of psA in the future.